- Home
- SEER vs OVID Comparison
SEER vs OVID Comparison
Compare SEER & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | OVID |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 117.5M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SEER | OVID |
|---|---|---|
| Price | $1.80 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 128.0K | ★ 1.6M |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,376,999.00 | $6,610,000.00 |
| Revenue This Year | $22.37 | $1,077.56 |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.11 | ★ 945.89 |
| 52 Week Low | $1.62 | $0.24 |
| 52 Week High | $2.41 | $2.01 |
Technical Indicators
Market Signals| Indicator | SEER | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 43.88 |
| Support Level | $1.84 | $1.50 |
| Resistance Level | $1.92 | $1.61 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.00 | 14.86 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.